CAMBRIDGE, Mass., Aug. 9, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the second quarter ended June 30, 2016.
"During the second quarter of 2016, we focused on execution across our pipeline of discovery and clinical-stage programs," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. "We look forward to a number of milestones in the second half of 2016, including preliminary data readouts for our three Phase 1 clinical trials, which we believe will demonstrate both the strength of our platform and our ability to effectively develop kinase therapies against difficult-to-drug targets. These data will help inform our clinical plans in the future, with the goal of developing treatments to dramatically improve the lives of people with cancer and other life-threatening diseases."
In April 2016, at the American Association for Cancer Research (AACR) Annual Meeting, Blueprint Medicines presented new preclinical data demonstrating that its RET inhibitors, including its drug candidate BLU-667, showed potent inhibition of activity in RET fusion positive lung adenocarcinoma and papillary thyroid cancer cell lines as well as medullary thyroid cancer cell lines driven by an activating RET point mutation. Blueprint Medicines' RET inhibitors retained in vitro and in vivo activity against RET resistant mutants that Blueprint Medicines predicts may arise in patients, which provides a potential opportunity for a meaningful and durable clinical response in RET-driven disease. Blueprint Medicines remains on track to file an IND for BLU-667 by the end of 2016.
In April 2016, Blueprint Medicines announced the appointment of Dr. Lynn Seely to its Board of Directors.
In the third quarter of 2016, Blueprint Medicines achieved a pre-clinical milestone of $1.0M under its collaboration with Alexion Pharma Holding (Alexion), which is expected to be paid during the third quarter of 2016.
Second Quarter 2016 Financial Results:
Cash Position: As of June 30, 2016, cash, cash equivalents, and investments were $172.6 million, as compared to $162.7 million as of December 31, 2015. This increase was primarily due to the $45.0 million upfront payment received in March 2016 under Blueprint Medicines' cancer immunotherapy collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche), offset by cash used in operating activities.
Collaboration Revenue: Collaboration revenues were $7.1 million for the second quarter of 2016, as compared to $2.7 million for the second quarter of 2015. This increase was due to increased activity in Blueprint Medicines' collaboration with Alexion and Blueprint Medicines entering into a collaboration with Roche in March 2016.
R&D Expenses: Research and development expenses were $21.3 million for the second quarter of 2016, as compared to $11.2 million for the same period in 2015. This increase was primarily attributable to increased manufacturing and clinical expenses associated with advancing BLU-285 and BLU-554 into clinical trials, increased pre-clinical expenses associated with advancing BLU-667 towards an IND filing, continuing to build Blueprint Medicines' platform and advance its discovery pipeline, and increased personnel-related expenses.
G&A Expenses: General and administrative expenses were $4.7 million for the second quarter of 2016, as compared to $3.8 million for the same period in 2015. This increase was primarily attributable to increased professional fees.
Net Loss: Net loss was $18.9 million for the second quarter of 2016, or a basic and diluted net loss per share available to common stockholders of $0.70, as compared to a net loss of $13.0 million for the same period in 2015, or a basic and diluted net loss per share available to common stockholders of $0.81.
Blueprint Medicines expects that its cash, cash equivalents and investments balance will be at least $120 million at December 31, 2016. Blueprint Medicines expects that its existing cash, cash equivalents and investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into early 2018.
Blueprint Medicines' lead drug candidates are BLU-285, a selective inhibitor of both Exon 17 mutant KIT and D842V mutant PDGFRα, and BLU-554, a selective inhibitor of the FGFR4 receptor. Enrollment continues to progress in the dose escalation portion of Blueprint Medicines' Phase 1 clinical trials for BLU-285 in unresectable, treatment-resistant gastrointestinal stromal tumors and advanced systemic mastocytosis and BLU-554 in advanced hepatocellular carcinoma. Blueprint Medicines expects to share preliminary data from the dose escalation portion of each of these Phase 1 clinical trials by the end of 2016. For each Phase 1 clinical trial, Blueprint Medicines anticipates that the preliminary data will include safety, pharmacokinetics and pharmacodynamic measures across a range of dose levels and any initial assessments of clinical activity that may be available.
Conference Call Information
Blueprint Medicines will host a live conference call and audio webcast today at 8:30 a.m. EDT. The conference call may be accessed by dialing 1-855-728-4793 (domestic) or 1-503-343-6666 (international) and referring to conference ID 33938424. An audio webcast of the conference call will also be available in the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans and timelines for the clinical development of BLU-285 and BLU-554; the timing of clinical data or proof of concept for preclinical and clinical programs, including, without limitation, the timing and type of preliminary clinical data for Blueprint Medicines' Phase 1 clinical trials for BLU-285 and BLU-554; the timing of regulatory submissions or filings, including, without limitation, an investigational new drug application for BLU-667; expectations regarding Blueprint Medicines' existing cash, cash equivalents and investments; and Blueprint Medicines' strategy, business plans and focus. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines' drug product candidates, including BLU-285 and BLU-554; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the efficacy and safety of its drug product candidates; the preclinical and clinical results for Blueprint Medicines' drug product candidates, which may not support further development of such drug product candidates; and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to develop and commercialize companion diagnostics for its current and future drug candidates, including a companion diagnostic for BLU-554 with Ventana Medical Systems, Inc.; and the success of Blueprint Medicines' rare genetic disease collaboration with Alexion Pharma Holding and its cancer immunotherapy collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, as filed with the Securities and Exchange Commission (SEC) on May 10, 2016, as amended by the Form 10-Q/A filed with the SEC on July 22, 2016, and other filings that Blueprint Medicines may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.
Blueprint Medicines Corporation
Selected Condensed Consolidated Balance Sheet Data
Cash, cash equivalents and investments
Unbilled accounts receivable
Working capital (1)
Term loan payable
Lease incentive obligation
Total stockholders' equity
(1) Blueprint Medicines defines working capital as current assets less current liabilities.
Blueprint Medicines Corporation
Condensed Consolidated Statements of Operations Data
(in thousands, except per share data)
Three Months Ended
Six Months Ended
Research and development
General and administrative
Total operating expenses
Other income (expense):
Other income (expense), net
Total other income (expense)
Convertible preferred stock dividends
Net loss applicable to common stockholders
Net loss per share applicable to common stockholders — basic and diluted
Weighted-average number of common shares used in net loss per share applicable to common stockholders — basic and diluted